Previous 10 | Next 10 |
Montrouge, France, June 26, 2020 DBV Technologies Provides Operational and Business Update BLA review of Viaskin Peanut for the treatment of peanut allergy in children ages 4-11 years ongoing Company to immediately initiate restructuring plan to extend cash runway while awaitin...
Aimmune Therapeutics (NASDAQ: AIMT) has performed significantly worse than the broader market of late. The company's stock fell by more than 50% during the first quarter of the year, and even though it has rebounded somewhat, Aimmune's shares are still down by 43% year to date. If Aimmune ca...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2020 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 ...
Montrouge, France, June 4, 2020 DBV Technologies to Present Data on Epicutaneous Immunotherapy and Food Allergy Quality of Life at EAACI Digital Congress 2020 Virtual presentations will include data about children with and without multiple food allergies from the pivotal Phase III peanu...
Montrouge, France, June 2, 2020 DBV Technologies To Present at the Goldman Sachs 41 st Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced th...
ShiftPixy PIXY -27% after pricing ~$12M public offering. More news on: GigaMedia Limited, Renren Inc., DBV Technologies S.A., Stocks on the move, , Read more ...
Gainers: Nano Dimension NNDM +272% . More news on: ShiftPixy, Inc., Mercurity Fintech Holding Inc., Iterum Therapeutics plc, Stocks on the move, , Read more ...
Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2020 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 ...
COVID-19 Is Distracting Investors from an Amazing Market Opportunity While the world remains hyper-focused on COVID-19 as the biggest healthcare challenge of the past century, it is perhaps easy to overlook progress being made to treat more mundane (yet far more durable) medical problems. ...
DBVT Technologies (NASDAQ: DBVT ) files an offer to sell ordinary shares of an indeterminate amount. More news on: DBV Technologies S.A., Tech stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
DBV Technologies S.A. Website:
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 ...
Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutic...
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expecte...